Valuation: InspireMD

Market Cap 3.21Cr 2.83Cr 2.67Cr 2.42Cr 4.55Cr 307.62Cr 4.59Cr 32Cr 12Cr 157.05Cr 12Cr 12Cr 504.38Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 3.21Cr 2.83Cr 2.67Cr 2.42Cr 4.55Cr 307.62Cr 4.59Cr 32Cr 12Cr 157.05Cr 12Cr 12Cr 504.38Cr EV / Sales 2026 *
3.27x
EV / Sales 2027 * 1.59x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2020
Director of Finance/CFO 58 25/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 02/06/2017
Director/Board Member 68 07/02/2013
Director/Board Member 62 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 3.21Cr
+1.26%+1.67%-24.46%+1.96% 11TCr
-0.10%-2.18%-23.52%-0.39% 1.13TCr
-0.01%-1.84%+98.39%+108.07% 934.81Cr
+0.33%-2.04%-49.55%-67.02% 411.38Cr
-1.79%+2.37%-23.53%+24.68% 248.75Cr
+4.54%-3.35%-5.26%-63.48% 202.37Cr
-0.20%-2.80% - - 189.93Cr
-0.58%-2.60%-23.08%-32.61% 151.78Cr
Average -0.04%+0.47%-7.29%-4.11% 1.73TCr
Weighted average by Cap. +0.99%+1.71%-16.40%+6.02%

Financials

2026 *2027 *
Net sales 97.99L 86.43L 81.75L 74.1L 1.39Cr 94Cr 1.4Cr 9.77Cr 3.77Cr 48Cr 3.68Cr 3.6Cr 154.19Cr 2.01Cr 1.78Cr 1.68Cr 1.52Cr 2.86Cr 193.21Cr 2.88Cr 20Cr 7.75Cr 99Cr 7.56Cr 7.39Cr 316.78Cr
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-